Michel MARRE
E-mail: michel.marre@bch.aphp.fr
MD, PhD
Paris, FRANCE

Current Position:
Head of Diabetes, Endocrinology and Nutrition Department in Hôpital BICHAT, Paris.
Professor of Endocrinology and Metabolism, Faculty of Medicine Xavier BICHAT, University Paris VII.
Director of the INSERM Research Unit U695 entitled « Genetic determinants of type 2 diabetes and its vascular complications ».

Special Area of Interest and Expertise:
1976-1980: Neural control of pancreatic endocrine secretions in the normal and diabetic rat.
Director: Prof. Roger ASSAN – Paris VI

1980-1982: Experimental studies of renin and kallikrein releases in the isolated perfused rat kidney. INSERM U36. Directors: Prof. Pierre CORVOL and Prof. Joël MENARD

1983-1987: Clinical studies on kidney function, hypertension and the use of ACE inhibitors in diabetic patients. Hôpital Saint-Louis, Paris. Director: Prof. Philippe PASSA. This period was inaugurated by a one-week period in Professor Carl-Erik MOGENSEN’s laboratory (Aarhus, Denmark), to set-up a radioimmunoassay for urinary albumin, and to learn renal clearance measurements, using radio-isotopes in humans.

1987 onwards: Clinical studies were pursuited in the same domain untill now, as head of Diabetes Unit in Angers University Hospital, and now as Head of the Diabetes Department in Hôpital BICHAT, Paris.

From 1994: Principal topic of interest dealt with the genetic factors influencing nephropathy in type 1 diabetes. This research was conducted principally in cooperation with Dr. F. ALHENC-GELAS (INSERM U367, Paris), and Prof. X. JEUNEMAITRE (INSERM U36, Paris).

Since 1994: A prospective follow-up study of 5 200 subjects of the French general population has been established in the Center-West part of France, in cooperation with Dr. E. ESCHWEGE, B. BALKAU, P. DUCIMETIERE (INSERM U258, Villejuif) and Dr. J. TICHET (IRSA, Tours), dealing with the components of the Insulin Resistance Syndrome (the « DESIR » study). DNA samples were collected at recruitment under Michel MARRE’s responsability.

Since 1995: A clinical trial has been setup in France, (and then in Europe and North Africa since 1997) comparing the usefulness of a low-dose of Ramipril, an ACE inhibitor, to placebo in type 2, non-insulin-dependent diabetic patients. End of study: 31th March 2001, DNA samples were collected from the French participants at inclusion into the study. Principal investigator: Michel MARRE.

Other Activities:
Past Member of the Committee of the EASD (European Association for the Study of Diabetes).
Past President of the European Diabetic Nephropathy Study Group.
Member of:
ALFEDIAM (Association de Langue Française pour l’Etude du DIAbète et des maladies Métaboliques)
EASD (European Association for the Study of Diabetes), ADA (American Diabetes Association), Société Française d’Endocrinologie, Société Française d’Hypertension Artérielle, European Society of Hypertension

Editorial boards and Publications:
Reviewer for the following journals:
Diabetes and Metabolism, Diabetologia,Diabetes,Diabetes Care,Journal of the American Society of Nephrology, Kidney International, American Journal of Kidney Disease, Circulation, La Presse Médicale, The Lancet

Five relevant publications :

- MARRE M., CHATELLIER G., LEBLANC H., GUYENNE T.T., MENARD J., PASSA P.
Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
British Medical Journal, 1988, 297: 1092-1095.

- MARRE M., JEUNEMAITRE X., GALLOIS Y, RODIER M., CHATELLIER G., SERT C., DUSSELIER L., KAHAL Z., CHAILLOUS L., HALIMI S., MULLER A., SACKMANN H., BAUDUCEAU B., BLED F., PASSA Ph. and ALHENC-GELAS F.
Génétique de la Néphropathie Diabétique (GENEDIAB) Study Group. Contribution of Genetic Polymorphism in the Renin-Angiotensin System to the Development of Renal Complications in Insulin-dependent Diabetes. The Journal of Clinical Investigation, 1997, 99 : 1585-1595.

- MARRE M., BOUHANICK B., BERRUT G., GALLOIS Y., LE JEUNE J.J., CHATELLIER G., MENARD J., ALHENC-GELAS F. Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 Diabetes. Hypertension, 1999, 33 : 775-780.

- HADJADJ S., BELLOUM R., BOUHANICK B., GALLOIS Y., GUILLOTEAU G., CHATELLIER G., ALHENC-GELAS F., MARRE M. Prognostic value of angiotensin-I converting enzyme D/I polymorphism for nephropathy in type 1 diabetes: a prospective study. Journal of the American Society of Nephrology, 2001, 12: 541-549.

- WEEKERS L, BOUHANICK B, HADJADJ S, GALLOIS Y, ROUSSEL R, PEAN F, ANKOTCHE A, CHATELLIER G, ALHENC-GELAS F, LEFEBVRE PJ, MARRE M. Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes. 2005 Oct;54(10):2961-7.

Cette page est également disponible en : Anglais